FDA Rejects Outlook Therapeutics’ Eye Drug for Second Time in 2025
-
LN24 / 4 months
- 0
- 2 min read
The U.S. Food and Drug Administration (FDA) has once again declined to approve Outlook Therapeutics’ drug for a type of eye disease, marking a second rejection in 2025 and prompting a sharp drop in the company’s shares. The drug, Lytenava, was being developed to treat wet age-related macular degeneration (AMD), a chronic eye condition that […]